Nancy Davis

7PUBLICATIONS
93CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 01, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

Amanda Nizam, Charles B Nguyen, Jinju Li

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Jan 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Petros Grivas, Damien Pouessel, Chandler H Park

|Aug 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline Update.

Rahul Seth, Sanjiv S Agarwala, Hans Messersmith

|Oct 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.

Joseph W Kim, Rana R McKay, Marc R Radke

|Aug 12, 2022
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Yu-Wei Chen, Matthew D Tucker, Landon C Brown

Pageof 2

Frequent Collaborators

3 joint publications

Petros Grivas

3 joint publications

Daniel P Petrylak

2 joint publications

Chethan Ramamurthy

2 joint publications

Yohann Loriot